Inspiremd Stock Performance
| NSPR Stock | USD 2.77 0.06 2.21% |
InspireMD has a performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.63, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, InspireMD's returns are expected to increase less than the market. However, during the bear market, the loss of holding InspireMD is expected to be smaller as well. InspireMD right now retains a risk of 3.08%. Please check out InspireMD downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to decide if InspireMD will be following its current trending patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in InspireMD are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile basic indicators, InspireMD may actually be approaching a critical reversion point that can send shares even higher in February 2025. ...more
| Begin Period Cash Flow | 4.6 M |
InspireMD |
InspireMD Relative Risk vs. Return Landscape
If you would invest 265.00 in InspireMD on October 12, 2024 and sell it today you would earn a total of 12.00 from holding InspireMD or generate 4.53% return on investment over 90 days. InspireMD is currently generating 0.1186% in daily expected returns and assumes 3.0775% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than InspireMD, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
InspireMD Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for InspireMD's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as InspireMD, and traders can use it to determine the average amount a InspireMD's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0385
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | NSPR | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.08 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average InspireMD is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of InspireMD by adding it to a well-diversified portfolio.
InspireMD Fundamentals Growth
InspireMD Stock prices reflect investors' perceptions of the future prospects and financial health of InspireMD, and InspireMD fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on InspireMD Stock performance.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.37 | ||||
| Operating Margin | (4.68) % | ||||
| Current Valuation | 31.51 M | ||||
| Shares Outstanding | 26.08 M | ||||
| Price To Earning | (0.16) X | ||||
| Price To Book | 1.71 X | ||||
| Price To Sales | 10.59 X | ||||
| Revenue | 6.21 M | ||||
| EBITDA | (20.91 M) | ||||
| Cash And Equivalents | 26.47 M | ||||
| Cash Per Share | 3.18 X | ||||
| Total Debt | 1.59 M | ||||
| Debt To Equity | 0.07 % | ||||
| Book Value Per Share | 1.61 X | ||||
| Cash Flow From Operations | (16.38 M) | ||||
| Earnings Per Share | (0.71) X | ||||
| Total Asset | 47.64 M | ||||
| Retained Earnings | (221.5 M) | ||||
| Current Asset | 4.63 M | ||||
| Current Liabilities | 6.83 M | ||||
About InspireMD Performance
Assessing InspireMD's fundamental ratios provides investors with valuable insights into InspireMD's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the InspireMD is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel. Inspiremd operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 50 people.Things to note about InspireMD performance evaluation
Checking the ongoing alerts about InspireMD for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for InspireMD help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| InspireMD had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 6.21 M. Net Loss for the year was (19.92 M) with profit before overhead, payroll, taxes, and interest of 1.12 M. | |
| InspireMD currently holds about 26.47 M in cash with (16.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.18, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 17.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing InspireMD's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether InspireMD's stock is overvalued or undervalued compared to its peers.
- Examining InspireMD's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating InspireMD's management team can have a significant impact on its success or failure. Reviewing the track record and experience of InspireMD's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of InspireMD's stock. These opinions can provide insight into InspireMD's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for InspireMD Stock Analysis
When running InspireMD's price analysis, check to measure InspireMD's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InspireMD is operating at the current time. Most of InspireMD's value examination focuses on studying past and present price action to predict the probability of InspireMD's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InspireMD's price. Additionally, you may evaluate how the addition of InspireMD to your portfolios can decrease your overall portfolio volatility.